Sign up
Pharma Capital

Trading in Trevena shares halted as FDA reviews company's pain treatment drug

The regulator is due to make a decision whether to approve the drug's use in November
An injection
Trevena is a biopharmaceutical company focused on pain treatments

Trading in the shares of Trevena Inc (NASDAQ:TRVN) were halted on Thursday because the US Food and Drug Administration’s is reviewing its pain drug for adult patients.

The government's Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) is meeting all day to review oliceridine, a product developed by Trevena for the management of moderate to severe acute pain in adult patients for whom an intravenous (IV) opioid is warranted. 

Trevena’s New Drug Application (NDA) submission for oliceridine was accepted by the FDA on January 2, 2018, with a PDUFA target date for completion of review by the FDA of November 2, 2018.

The AADPAC reviews and evaluates available data concerning the safety and effectiveness of marketed drug products for use in anesthesiology and surgery and makes recommendations to the FDA. 

READ: Trevena shares pop on successful completion of Phase 1 study of acute migraine treatment

The FDA is not bound by the Advisory Committee’s recommendations but takes its advice into consideration when making its decisions.

Oliceridine is a G-protein biased mu-opioid receptor (MOR) ligand in development to manage moderate to severe acute pain in hospitals or other controlled clinical settings and where intravenous (IV) therapy is justified.

Shares of Trevena were trading very early in the premarket on Thursday at $0.94, having closed on Wednesday 11.5% down at $0.947.

Trevena is a biopharmaceutical company focused on the development and commercialization of new treatment options for patients in pain.

The company is based in Chesterbrook, Pennsylvania.



Register here to be notified of future TRVN Company articles
View full TRVN profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.